J Neurogastroenterol Motil 2021; 27(1): 147-148  https://doi.org/10.5056/jnm20244
Impact of Helicobacter pylori-related Metabolic Syndrome and Gastroesophageal Reflux Disease on the Risk of Acute Myocardial Infarction
Jannis Kountouras,1* Apostolis Papaefthymiou,1,2,3 Michael Doulberis,1,3,4 Stergios A Polyzos,3 Christos Zavos,1 Evangelos Kazakos,1,5 Sofia K Tzika,1 Elisabeth Vardaka,1,6 Christos Liatsos,7 and Panagiotis Katsinelos1
1Department of Medicine, Second Medical Clinic, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Macedonia, Greece
2Department of Gastroenterology, University Hospital of Larisa, Mezourlo, Larisa, Greece
3First Laboratory of Pharmacology, Aristotle University of Thessaloniki, Thessaloniki, Macedonia, Greece
4Division of Gastroenterology and Hepatology, Medical University Department, Kantonsspital Aarau, Aarau, Switzerland
5Faculty of Midwifery, School of Health Sciences, University of Western Macedonia, Greece
6Department of Nutritional Sciences and Dietetics, School of Health Sciences, International Hellenic University, Alexander Campus, Thessaloniki, Macedonia, Greece
7Department of Gastroenterology, 401 General Military Hospital of Athens, Athens, Greece
Published online: January 30, 2021.
© The Korean Society of Neurogastroenterology and Motility. All rights reserved.


TO THE EDITOR: In their recent study, Eisa et al1 concluded that gastroesophageal reflux disease (GERD) with concomitant metabolic syndrome (MetS) parameters is a risk factor of acute myocardial infarction (AMI) though this risk may be clinically insignificant.

In this regard, there is increasing evidence for association between Helicobacter pylori infection (Hp-I) and insulin resistance (IR) or MetS and related morbidity, including GERD and cardiovascular disease (CVD);2,3 the prevalence of MetS is higher in Hp-positive people;2 Hp-linked MetS is a risk factor of GERD and its eradication exhibits a positive effect against GERD in certain populations;3 AMI, a potentially fatal CVD complication, is closely linked with MetS;2 and Hp is a risk for acute coronary syndrome (ACS) including AMI,2 thus further investigation is warranted to estimate whether Hp eradication affects AMI occurrence.

Specifically, both Hp-I and MetS are highly prevalent worldwide and epidemiological studies as well as meta-analyses have shown that obesity induces inflammation (especially abdominal, visceral obesity) and drives to MetS, thereby being an indirect risk factor for GERD.3 In this respect, the conventional claim that declining Hp prevalence has led to a rise in GERD requires to be better studied since, for instance, the current global prevalence of Hp-I varies from 39.9% to 84.2% whereas the comparable picture for GERD is quite less varying from 2.5% to 51.2%.4 Moreover, several data indicate that Hp may contribute to GERD pathogenesis by several mechanisms and its eradication results in adequate control of GERD symptoms and improves esophagitis.3,5

A recent meta-analysis also indicated that Hp-I increases the risk of CVD adverse events, particularly AMI;6 there is a link between Hp-related CagA cytotoxin and ACS and the odds ratio of AMI is twice as greater in Hp-positive patients. Likewise, MetS is a major risk factor for AMI,7 increases the risk of CVD adverse events more than 2-fold, whereas its recovery significantly decreases the risk for major adverse cardiovascular events including AMI. Moreover, Hp-I is an independent risk factor for atrial fibrillation (AF),8 which remains a frequent arrhythmia in AMI and is closely linked with augmented subsequent cardiovascular mortality; coronary artery disease is a risk factor for AF and coronary embolism due to AF is a cause of AMI; and Hp-related non-alcoholic fatty liver disease, the hepatic component of MetS, is a risk of AF.8 Finally, Hp-I–related MetS may contribute to the pathophysiology of CVD including AMI by several mechanisms,9,10 thereby signifying eradication therapy as AMI prevention strategy.

Financial support


Conflicts of interest


Author contributions

All the authors have helped in the drafting and writing of the manuscript.

  1. Eisa M, Sandhu A, Prakash R, Ganocy SJ, Fass R. The risk of acute myocardial infarction in patients with gastroesophageal reflux disease. J Neurogastroenterol Motil 2020;26:471-476.
    Pubmed KoreaMed CrossRef
  2. Franceschi F, Gasbarrini A, Polyzos SA, Kountouras J. Extragastric diseases and Helicobacter pylori. Helicobacter 2015;20:40-46.
    Pubmed CrossRef
  3. Kountouras J, Polyzos SA, Doulberis M, et al. Potential impact of Helicobacter pylori-related metabolic syndrome on upper and lower gastrointestinal tract oncogenesis. Metabolism 2018;87:18-24.
    Pubmed CrossRef
  4. Kountouras J, Doulberis M, Papaefthymiou A, et al. A perspective on risk factors for esophageal adenocarcinoma: emphasis on Helicobacter pylori infection. Ann N Y Acad Sci 2019;1452:12-17.
    Pubmed CrossRef
  5. Kountouras J, Zavos C, Chatzopoulos D. H pylori infection and reflux oesophagitis. Gut 2004;53:912.
    Pubmed KoreaMed
  6. Wang B, Yu M, Zhang R, Chen S, Xi Y, Duan G. A meta-analysis of the association between Helicobacter pylori infection and risk of atherosclerotic cardiovascular disease:e12761.
    Pubmed KoreaMed CrossRef
  7. Sarkar S, Paul BK, Chakraborty PK, et al. Association between metabolic syndrome and acute myocardial infarction (AMI). Mymensingh Med J 2016;25:628-634.
  8. Kountouras J, Doulberis M, Papaefthymiou A, Polyzos SA. Impact of Helicobacter pylori-linked metabolic syndrome on non-alcoholic fatty liver disease and its connected atrial fibrillation risk. Liver Int 2020;40:2036-2037.
    Pubmed CrossRef
  9. Kountouras J, Polyzos SA, Katsinelos P, et al. Cardio-cerebrovascular disease and Helicobacter pylori-related metabolic syndrome: we consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. Int J Cardiol 2017;229:17-18.
    Pubmed CrossRef
  10. Boziki M, Grigoriadis N, Doulberis M, Papaefthymiou A, Polyzos SA, Kountouras J. Potential impact of Helicobacter pylori-related Galectin-3 on chronic kidney, cardiovascular and brain disorders in decompensated cirrhosis. Dig Liver Dis 2020;52:121-123.
    Pubmed CrossRef

This Article

Cited By Articles
  • CrossRef (0)

Author ORCID Information

Social Network Service



Aims and Scope